Integrated Filing — IndAS



General information about company

Scrip Code 544172
NSE Symbol INDGN
MSEI Symbol NOTLISTED
ISIN INE065X01017
Name of company Indegene Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 30-10-2025   18:30:00
End date and time of board meeting 30-10-2025   19:05:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 80,420.00 1,56,500.00
Other income 1,970.00 4,180.00
Total income 82,390.00 1,60,680.00
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 51,580.00 99,730.00
(e) Finance costs 380.00 750.00
(f) Depreciation, depletion and amortisation expense 2,340.00 4,500.00
(f) Other Expenses
1 Other expenses 14,780.00 27,180.00
Total other expenses 14,780.00 27,180.00
Total expenses 69,080.00 1,32,160.00
3 Total profit before exceptional items and tax 13,310.00 28,520.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 13,310.00 28,520.00
6 Tax expense
7 Current tax 3,790.00 6,630.00
8 Deferred tax (690.00) 40.00
9 Total tax expenses 3,100.00 6,670.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 10,210.00 21,850.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 10,210.00 21,850.00
17 Other comprehensive income net of taxes 4,840.00 6,510.00
18 Total Comprehensive Income for the period 15,050.00 28,360.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 10,210.00 21,850.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 4,800.00 4,800.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.26 9.12
Diluted earnings (loss) per share from continuing operations 4.23 9.05
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.26 9.12
Diluted earnings (loss) per share from continuing and discontinued operations 4.23 9.05
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) All amounts in INR millions except share data and where otherwise stated 1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote amounts less than INR half a million 2 The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 29 October 2025 and approved by the Board of Directors at its meeting held on 30 October 2025 The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2025 and have issued an unmodified review report on the same 3 The Consolidated Financial Results for the quarter and six months ended 30 September 2025 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL wwwbseindia com and on the Company s website URL www indegene com investor relations 4 Acquisition of MJL Communications Group Ltd On 25 March 2025 the Group had obtained control of MJL Communications Group Ltd MJL by acquiring 100 percent of its shares The acquisition was consummated for a consideration of INR 411 which includes earnout payment of INR 150 The contingent consideration is based on the performance of MJL during the fiscal year beginning 01 April 2025 and ending 31 March 2027 and range of contingent consideration payable is between Nil to INR 172 The Group has concluded that the acquisition is business and did the provisional PPA for the same during year ended 31 March 2025 which was finalised during the six months ended 30 September 2025 The fair value of net assets acquired on the acquisition date as a part of the transaction amounted to INR 98 The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to INR 174 and goodwill aggregating to INR 139



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 16,130.00
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 37,940.00
Other intangible assets 17,880.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 1,930.00
Total non-current financial assets 1,930.00
Deferred tax assets (net) 9,120.00
Other non-current assets 1,440.00
Total non-current assets 84,440.00
2 Current assets
Inventories 0.00
Current financial asset
Current investments 77,830.00
Trade receivables, current 78,700.00
Cash and cash equivalents 36,830.00
Bank balance other than cash and cash equivalents 12,150.00
Loans, current 0.00
Other current financial assets 280.00
Total current financial assets 2,05,790.00
Current tax assets (net) 3,590.00
Other current assets 63,750.00
Total current assets 2,73,130.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,57,570.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,800.00
Other equity 2,81,760.00
Total equity attributable to owners of parent 2,86,560.00
Non controlling interest 0.00
Total equity 2,86,560.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 9,990.00
Total non-current financial liabilities 9,990.00
Provisions, non-current 5,970.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 15,960.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 200.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 8,950.00
Total Trade payable 9,150.00
Other current financial liabilities 16,390.00
Total current financial liabilities 25,540.00
Other current liabilities 20,340.00
Provisions, current 7,920.00
Current tax liabilities (Net) 1,250.00
Deferred government grants, Current 0.00
Total current liabilities 55,050.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 71,010.00
Total equity and liabilites 3,57,570.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) 6 Final dividend for the financial year 2024 25 of INR 2 per share was approved by the shareholders at the 27th Annual General Meeting held on 26 June 2025 and the same was paid on 30 June 2025 7 As on 30 September 2025 the Group has entered into a stock purchase agreement with BioPharm Parent Holding Inc and Engage Acquisition Corp Seller to acquire 100 percent interest in BioPharm Parent Holding Inc BioPharm a specialized marketing services agency part of Omnicom Health Group for an aggregate purchase consideration of INR 9146 USD 104 million including deferred and earn out consideration with effective date being 01 October 2025 This acquisition is expected to strengthen Groups commercialization portfolio with AdTech combining AI and digital advertising enabling pharma companies to drive more precise scalable and measurable outcomes Accordingly, the Group has transferred the upfront purchase consideration of INR 5519 USD 62 million payable to the Seller as per the stock purchase agreement to the Escrow agent s account on 30 September 2025 and the same has been disclosed as part of the other current assets as on 30 September 2025 The same has been subsequently transferred to the Seller on 01 October 2025 The Group is currently in the process of allocating the purchase consideration to identifiable assets and liabilities of BioPharm 8 During the year 2020 21 the Group was named in a class action lawsuit filed in the US District Court of New Jersey alleging non compliance with the Telephone Consumer Protection Act of 1991 TCPA by sending unsolicited fax advertisements without the recipients prior express invitation or permission In July 2025 the Court allowed the case to proceed as a class action The Groups request to challenge this decision was not accepted The matter remains ongoing and is progressing toward trial or potential settlement Mediation discussions are expected in early 2026 with the Group participating on a no admission of liability basis As of 30 September 2025 no settlement terms have been proposed or agreed and the scope of potential claimants remains uncertain Any financial obligation would depend on valid claims being filed and cannot be reliably estimated Accordingly no provision is considered necessary in the consolidated financial results at this stage 9 Subsequent to the quarter and six months ended 30 September 2025 the Group has acquired 100 percent stake in the Warn and Co Limited acquired company a UK based Company providing business transformation consulting solutions around change management organisation design and solution design by way of Share Purchase agreement dated 16 October 2025 to acquire 100 percent shares of the acquired company for a purchase consideration approximating to GBP 3 millions subject to working capital adjustments Notes to Assets and Liabilites: a Property plant and equipment includes Right-of-use assets of INR 1145 b Other non-current asset consists of Non-current tax assets net of INR 106 and Other non-current asset of INR 39 c Trade receivables current consists Billed Revenue INR 6865 and Unbilled revenue of INR 1005 d Other non current financial liabilities consists of lease liabilities of INR 882 and Other financial Liabilities INR 117 e Other current financial liabilities consists of lease liabilities INR 338 and other financial liabilities of INR 1301



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Enterprise Medical Solutions 22,420.00 43,740.00
2 Enterprise Commercial Solutions 48,740.00 93,270.00
3 Brand Activation 6,380.00 13,960.00
4 Others 2,880.00 5,530.00
Total Segment Revenue 80,420.00 1,56,500.00
Less: Inter segment revenue 0.00 0.00
Revenue from operations 80,420.00 1,56,500.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Enterprise Medical Solutions 5,750.00 11,510.00
2 Enterprise Commercial Solutions 10,230.00 20,710.00
3 Brand Activation (410.00) 100.00
4 Others (590.00) (1,090.00)
Total Profit before tax 14,980.00 31,230.00
i. Finance cost 380.00 750.00
ii. Other Unallocable Expenditure net off Unallocable income 1,290.00 1,960.00
Profit before tax 13,310.00 28,520.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Enterprise Medical Solutions 0.00 0.00
2 Enterprise Commercial Solutions 0.00 0.00
3 Brand Activation 0.00 0.00
4 Others 0.00 0.00
Total Segment Asset 0.00 0.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 0.00 0.00
4 Segment Liabilities
Segment Liabilities
1 Enterprise Medical Solutions 0.00 0.00
2 Enterprise Commercial Solutions 0.00 0.00
3 Brand Activation 0.00 0.00
4 Others 0.00 0.00
Total Segment Liabilities 0.00 0.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 0.00 0.00
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 5 The Segment results of the Group has been prepared in accordance with Ind AS 108 on Operating Segments The Group has identified business segments industry practice as reportable segments The reportable business segments comprise 1 Enterprise Medical Solutions 2 Enterprise Commercial Solutions 3 Brand Activation Effective 1 April 2025 the Omnichannel Activation segment has been renamed as Brand Activation Others mainly comprises of consultancy and clinical business Notes on Segment information Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker In deciding how to allocate resources and assessing performance the Groups chief operating decision maker is the Chief Executive Officer and Executive Director Assets and liabilities used in the Groups business are not identified to any of the operating segments as these are used interchangeably between segments Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous Other unallocable expenditure net of unallocable income for the three months ended 30 Sep 2025 includes depreciation and amortisation expense INR 234 and unallocable expenses INR 93 net of other income INR 197 Other unallocable expenditure net of unallocable income for the Six months ended 30 Sep 2025 includes depreciation and amortisation expense INR 450 and unallocable expenses INR 164 net of other income INR 418 Statement of Cash Flow includes following aggregations 1 Cash flows from Operating Activities Other adjustments to reconcile profit loss includes a Gain on termination of lease negative INR 3 b Loss on sale of fixed assets negative INR 1 c Net gain on disposal fair valuation of investments negative INR 187 d Expected credit loss on trade receivables and advances negative INR 1 e Bad debts written off negative INR 1 2 Cash flows from Investing Activities Other Inflow Outflows of cash includes a Purchase of investments accounted using FVTPL negativeINR 20516 b Proceeds from redemption of investments INR 25817 c Investments in fixed deposits negative INR 1968 d Redemption or maturity of fixed deposit INR 2089 Other cash payments to acquire equity or debt instruments of other entities consists of Amount Trasfer to Escrow agent for acquisition INR 5519 3 Cash flows from Financing Activities Proceeds from issuing shares is net of share issue expenses



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation 240.00 360.00
Total Amount of items that will not be reclassified to profit and loss 240.00 360.00
2 Income tax relating to items that will not be reclassified to profit or loss 60.00 90.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating the financial statements of foreign operations 4,660.00 6,240.00
Total Amount of items that will be reclassified to profit and loss 4,660.00 6,240.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 4,840.00 6,510.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 28,520.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 590.00
Adjustments for decrease (increase) in inventories 0.00
Adjustments for decrease (increase) in trade receivables, current (200.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 1,920.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (3,520.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4,500.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 1,520.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (40.00)
Adjustments for dividend income 0.00
Adjustments for interest income 2,350.00
Adjustments for share-based payments 1,150.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (1,930.00)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,640.00
Net cash flows from (used in) operations 30,160.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 9,880.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 20,280.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 55,190.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 1,570.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 2,860.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 54,220.00
Net cash flows from (used in) investing activities 320.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 280.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 1,830.00
Dividends paid 4,800.00
Interest paid 10.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (6,360.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 14,240.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (1,510.00)
Net increase (decrease) in cash and cash equivalents 12,730.00
Cash and cash equivalents cash flow statement at beginning of period 24,100.00
Cash and cash equivalents cash flow statement at end of period 36,830.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells Yes 30-04-2028